Andrew C. Orth Net Worth

The estimated Net Worth of Andrew C. Orth is at least $2.5 Million dollars as of 9 June 2023. Andrew Orth owns over 12,500 units of Krystal Biotech Inc stock worth over $2,504,754 and over the last 3 years Andrew sold KRYS stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Andrew Orth KRYS stock SEC Form 4 insiders trading

Andrew has made over 1 trades of the Krystal Biotech Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Andrew exercised 12,500 units of KRYS stock worth $794,375 on 9 June 2023.

The largest trade Andrew's ever made was exercising 12,500 units of Krystal Biotech Inc stock on 9 June 2023 worth over $794,375. On average, Andrew trades about 3,125 units every 0 days since 2021. As of 9 June 2023 Andrew still owns at least 12,600 units of Krystal Biotech Inc stock.

You can see the complete history of Andrew Orth stock trades at the bottom of the page.

What's Andrew Orth's mailing address?

Andrew's mailing address filed with the SEC is C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH, PA, 15203.

Insiders trading at Krystal Biotech Inc

Over the last 7 years, insiders at Krystal Biotech Inc have traded over $166,816,526 worth of Krystal Biotech Inc stock and bought 536,800 units worth $5,949,380 . The most active insiders traders include Daniel Janney, Dino A Rossi, and Krish S Krishnan. On average, Krystal Biotech Inc executives and independent directors trade stock every 40 days with the average trade being worth of $8,043,043. The most recent stock trade was executed by Suma Krishnan on 11 June 2024, trading 50,000 units of KRYS stock currently worth $8,788,000.

What does Krystal Biotech Inc do?

krystal biotech, inc. is using gene therapy to develop effective and novel treatments for skin diseases. our goal is to make a meaningful difference in the lives of underserved patient populations with debilitating skin diseases. we work to accomplish that through scientific innovation, operational excellence and believe that “nature operates in the shortest way possible”. (aristotle)

Complete history of Andrew Orth stock trades at Krystal Biotech Inc

Krystal Biotech Inc executives and stock owners

Krystal Biotech Inc executives and other stock owners filed with the SEC include:

• Krish S. Krishnan M.B.A., M.S.,
  Founder, Chairman, Pres & CEO
• Krish S. Krishnan,
  Chairman, Pres & CEO
• Dr. Andreas C. Orth,
  Exec. VP & Chief Commercial Officer
• Suma M. Krishnan,
  Founder, COO & Director
• Krish Krishnan,
  Chairman of the Board, President, Chief Executive Officer
• Suma Krishnan,
  Founder, Chief Operating Officer, Director
• Pooja Agarwal,
  Senior Vice President, Product Development
• Kathryn A. Romano,
  Chief Accounting Officer
• R. Douglas Norby,
  Lead Independent Director
• Dino Rossi,
  Independent Director
• Daniel Janney,
  Independent Director
• Julian Gangolli.,
  Independent Director
• Ashley Robinson,
  IR Contact Officer
• Kirti Ganorkar,
  Independent Director
• J. Christopher Naftzger,
  Chief Legal Officer, Corporate Secretary
• Jennifer Chien,
  Chief Commercial Officer
• Kathryn Romano,
  Chief Accounting Officer
• David Glynn,
  Gen. Counsel, Commercial & Compliance
• Meg Dodge,
  VP of Investor Relations & Corp. Communications
• Dr. Jing L. Marantz M.B.A., M.D., Ph.D.,
  Chief Bus. Officer
• Pooja Agarwal,
  Sr. VP of Product Devel.
• Whitney Glad Ijem,
  Sr. VP of Strategy & Bus. Devel.
• Josh Suskin,
  Director of HR & Operations
• Katherine Tuminello,
  HR & Office Mang.
• John Karakkal,
  VP of North American Sales and Marketing
• Gloria Lin,
  Accounting Mang.
• Catherine Mazzacco,
  Director
• Krish S Krishnan,
  President and CEO
• Antony A Riley,
  Chief Financial Officer
• Jennifer Kayden Lee,
  Chief Commercial Officer
• Christopher Mason,
  Director
• Jing L. Marantz,
  Chief Business Officer
• Everett Rand Sutherland,
  Director